A Comparative Analysis of Alkylating Agent and Epipodophyllotoxin-Related Leukemias

References

• Auclerc G., Jacquillat C., Auclerc M. F., Weil M., Bernard J. Post therapeutic leukemia. Cancer 1979; 44: 2017–2025
   PubMed Web of Science ®Google Scholar
• Kyle R. A. Second malignancies associated with che-motherapeutic agents. Semin. Oncol. 1982; 9: 131–142
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J., Philip P., Tinggaard Pedersen W., et al. Acute nonlymphocytic leukemia. preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. Cancer 1984; 54: 452–462
   PubMed Web of Science ®Google Scholar
• Koeffler H. P. Syndromes of acute non lymphocytic leukemia. Ann. Intern. Med. 1987; 107: 748–758
   PubMed Web of Science ®Google Scholar
• Levine E. G., Bloomfield C. D. Secondary mye-lodysplastic syndromes and leukemias. Clin. Hematol. 1986; 15: 1037–1080
   PubMedGoogle Scholar
• Pedersen Bjergaard J., Larsen S. O., Struck J., et al. Risk of therapy related leukemia and preleukcmia after Hodg-kin's disease. Lancet 1987; 329: 83–88
   Google Scholar
• Vaughn W. P., Karp J. E., Burke P. J. Effective chemotherapy of acute myelocytic leukemia occurring after alkylating agent or radiation therapy for prior malignancy. J. Clin. Oncol. 1983; 3: 204–207
   Google Scholar
• Devore R., Whitlock J., Heinsworth J. D., Johnson D. H. Therapy related acute non lymphocytic leukemia with monocytic features and rearrangement of chromosome 11q. Ann. Int. Med. 1989; 110: 740–742
   PubMedGoogle Scholar
• Whitlock J. A., Greer J. P., Lukens J. N. Epi-podophyllotoxin-related leukemia. Cancer 1991; 68: 600–604
   PubMed Web of Science ®Google Scholar
• Hon-Pui C., Ribeiro R. C., Hancock M. L. Acute myeloid leukemia in children treated with epipodo-phyllotoxins lor acute lymphoblastic leukemia. N. Engl. J. Med 1991; 325: 1682–1687
   PubMed Web of Science ®Google Scholar
• Hawkins M. M., Kinnier Wilson L. M., Stovell M. A., Marsden H. B., Potok M. H. N., Kingston J. E., Ches-Sels J. M. Epipodophyllotoxina, alkylating agents and radiation and risk of secondary leukemia alter childhood cancer. Br. Med J. 1992; 304: 951–958
   PubMed Web of Science ®Google Scholar
• Calabresi P., Chabner H. A. Antineoplastic agents. The, Pharmacological Basis of Therapeutics8th Ed., A. G. Gilman, T. W. Rall, A. S. Nies, P. Taylor. Pergamon Press, New York 1991; 1239–1240
   Google Scholar
• O'Dwyer P. J., Leyland-Jones B., Alonso M. T., Marsoni S., Wittes R. E. Etoposide (VP 16–213). Current status of an active anticancer drug. N. Engl. J. Med. 1985; 312: 692–700
   PubMed Web of Science ®Google Scholar
• Aisenberg A. C. Acute nonlymphocytic leukemia after treatment lor Hodgkin's disease. Am. J. Med. 1983; 75: 449–454
   PubMed Web of Science ®Google Scholar
• Yahalom J., Weshler Z., Fuks Z., Polliack A. Therapy related secondary leukemia complicating three different treatment modalities for Hodgkin'a disease. Immunol. Hematol. Res. Monograph. 1986; 2: 289–292
   Google Scholar
• Pedersen-Bjergaard J., Ersboll J., Sorensen H. M., et al. Risk of acute nonlymphocytic leukemia and prelcukemia in patients treated with cyclophosphamide for non-Hodpkin's lymphomas. Ann. Int. Med. 1985; 103: 195–200
   PubMed Web of Science ®Google Scholar
• Ellis M., Lishner M. Second malignancies after treatment for non-Hodgkin's lymphoma: A review. Leuk. Lymph. 1992, in press
   Google Scholar
• Buckman R., Cuzick J., Galton D. A. G. Long term survival in myelomatosis. Br. J. Hematol. 1982; 52: 589–599
   PubMed Web of Science ®Google Scholar
• Greene M. H., Boice J. D., Creer B. E., et al. Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer. N. Engl. J. Med. 1982; 307: 1416–1421
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J., Osterich K., Hansen M., et al. Acute nonlymphocytic leukemia, preleukemia and solid tumors following intensive chemotherapy for small cell carcinoma of the lung. Blood. 1985; 66: 1373–1397
   Google Scholar
• Fisher H., Rockette H., Fisher E. R., et al. Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation. The NSABP experience. J. Clin. Oncol. 1985; 3: 1640–1658
   PubMed Web of Science ®Google Scholar
• Redinan J. R., Vurgin D., Arlin R. A., et al. Leukemia following treatment of germ cell tumors in men. J. Clin. Oncol. 1984; 2: 1080–1087
   PubMed Web of Science ®Google Scholar
• Stortt H., Fox W., Girling D. J., et al. Acute leukemia after husulphan. Br. Med. J. 1977; 2: 1513–1517
   PubMed Web of Science ®Google Scholar
• Greene M. H., Hanis E. L., Gershenson D. M., et al. Melphalan may be a more potent leukemogen than cyclophospharnide. Ann. Intern. Med. 1986; 105: 360–367
   PubMed Web of Science ®Google Scholar
• Curtis R. E., Boice I. D., Stovall M., Bernstein L., et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N. Eng. J. Med. 1992; 326: 1745–1751
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J., Philip P. Therapy-related malignancies: A review. Eur. J. Hematol. 1989; 42(Suppl 48)39–47
   Google Scholar
• Lishner M., Slingerland J., Ban J., Panzarella T., De-Gendorfer P., Sutcliffe S. Second malignant neoplasms in patients with non-Hodgkin's lymphoma. Hematol. Oncol. 1991; 9: 167–179
   Google Scholar
• Levine E. G., Bloomfield C. D. Leukemias and myelodyoplastic syndromes secondary to drug, radiation and environmental exposure. Sem. Oncol. 1982; 19: 47–84
   Google Scholar
• Rowley J. D., Golomb H. M., Vardirnan J. W. Nonrandom chromosome abnormalities in acute leukemia and dysmyelopoietic syndromes with previously treated malignant disease. Blood 1981; 58: 759–767
   PubMed Web of Science ®Google Scholar
• Michels S. D., McKenna R. W., Arthur D. R., Brun-Ning R. D. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: A clinical and morphologic study of 65 cases. Blood. 1985; 65: 1364–1372
   PubMed Web of Science ®Google Scholar
• Vaughn W. P., Karp J. E., Burke P. J. Effective chemotherapy of acute myelocytic leukemia occurring after alkylating agent or radiation therapy for prior malignancy. J. Clin. Oncot. 1983; 3: 204–207
   Google Scholar
• Preisler H. D., Early A. P., Raza A., et al. Therapy of secondary acute nonlymphocytic leukemia with cytardbine. N. Engl. J. Med. 1983; 308: 21–23
   PubMed Web of Science ®Google Scholar
• Duane S. F., Peterson B. A., Bloomfield C. D., Michels S. D., Hurd D. D. Response of therapy associated acute nonlymphocytic leukemia to intensive induction chemotheraphy. Med. Ped. Oncol. 1985; 13: 207–213
   PubMedGoogle Scholar
• O'Dwyer P. J., Alonso M. T., Ley Land-Jones B., Mar-Soni S. Teniposide: a review of 12 years of experience. Cancer Treat. Rep. 1984; 68: 1455–1466
   PubMedGoogle Scholar
• Rubin C. M., Arthur D. C., Wood W. G., Large B. J., et al. Therapy related myelodysplastic syndrome and acute myeloid leukemia in children. Correlation between chromosomal abnormalities and prior therapy. Blood 1991; 78: 2982–2988
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J., Phillip P. Two different classes of therapy related and de novo acute myeloid leukemia. Cancer Genet. Cytogenet. 1991; 55: 119–124
   PubMed Web of Science ®Google Scholar
• Crane M. M., Kenting M. J., Trujillo J. M., et al. Environmental exposures in cytogenetically defined subsets of acute non-lymphocytic leukemia. JAMA 1989; 262: 634–639
   PubMed Web of Science ®Google Scholar
• Van Den Berghe H., Louwagie A., Broekaerl-Van Or-Shoven A., David E., et al. Chromosomal analysis in two unusual malignant blood disorders presumably induced by benzene. Blood 1979; 53: 558–566
   PubMed Web of Science ®Google Scholar
• Pedersen-Bjergaard J., Sigsaard T. C., Nielsen D., Gjedde S. B., Philip P., et al. Acute monocytic or myelo-monocytic leukemia with balanced chromosome transloca-tions to band 11q23 after therapy with 4–epidoxorubicin and cisplatin or cyclophosphamide for breast cancer. J. Clin. OnCol. 1992; 10: 1444–1451
   PubMed Web of Science ®Google Scholar
• Fourth International Workshop on chromosomes in leukemia. Secondary leukemia associated with neoplasia: treated and untreated. Cancer Genet. Cytogenet. 1984; 12: 95–104
   PubMedGoogle Scholar
• Le Beau M. M., Epstein M. D., et al. The interleukin 3 gene is located on human chromosome 5 and is deleted in myeloid leukemias with deletion of 5q. Proc. Nat. Acad. Sci. USA 1987; 84: 5913–5917
   PubMed Web of Science ®Google Scholar
• Le Beau M. M., Albain K., Larson R., et al. Clinical and cytogenetic correlations in 63 patients with therapy related myelodysplastic syndrome and acute non lymphocytic leukemia: further evidence for characteristic abnormalities of chromosome 5 and 7. J. Clin. Oncol. 1986; 4: 325–345
   PubMed Web of Science ®Google Scholar
• Murphree A. M., Benedict W. Retinoblastoma: Clues to human oncogenesis. Science 1984; 223: 1028–1033
   PubMed Web of Science ®Google Scholar
• Maraschin J., Dutrillaux B., Aurias A. Chromosome aberrations induced by etoposide (VP-16) are not random. Int. J. Concer 1990; 46: 808–832
   PubMed Web of Science ®Google Scholar
• Mirro J., Kitchingman G., Williams D., et al. Clinical and laboratory characteristics of acute leukemia with the 4; 11 translocation. Blood 1986; 67: 689–697
   PubMed Web of Science ®Google Scholar
• Kaneko Y., Maseki N., Takasaki N., et al. Clinical and hematologic characteristics in acute leukemia with 11q23 translocations. Blood 1986; 67: 484–491
   PubMed Web of Science ®Google Scholar
• De Taisne C., Gegonne A., Stehclin D., Bornheim A., Berger R. Chromosomal localisation of the human proto-oncogene c-ets. Nature 1984; 310: 581–583
   PubMed Web of Science ®Google Scholar
• Van Rijs J., Giguere V., Hurst J., et al. Chromosomal localisation of the human Thy-1 gene. Proc. Natl. Acad. Sci. USA 1985; 82: 5832–5835
   PubMed Web of Science ®Google Scholar
• Tunnacliffe A., Buluwela L., Kabbitts T. H. Physical lineage of three CD3 genes on chromosome 11. EMBO J. 1987; 6: 2953–2957
   PubMed Web of Science ®Google Scholar
• Nguyen C., Mattei M. G., Mattei J. F., Santoni M. J., Goridis C., Jordan B. R. Localisation of the human NCAM gene to band q23 of chromosome ll. J. Cell Biol. 1986; 102: 711–715
   PubMed Web of Science ®Google Scholar
• Diaz M. O., Lebeau M. M., Pitha P., Rowley J. D. Interferon and c-ets-l genes in the translocation (9; lI) (p2273) in human acute monocytic leukemia. Science 1986; 231: 265–267
   PubMed Web of Science ®Google Scholar
• Cimino G., Moin D. T., Canaani O., et al. Cloning of ALL-1, the locus involved in leukemias with the t(4;11) (q2173), t(9;1 1) (p2273) and t(11;19) (q23;q3) chromosome translocations. Cancer Res. 1991; 51: 6712–4
   PubMed Web of Science ®Google Scholar
• Van Der Poel S. Z., McCabe N. R., Gill H. J., et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc. Nat. Acad. Sci. USA 1991; 88: 10735–10739
   PubMed Web of Science ®Google Scholar